# 20 stocks in focus: Signature Global, IndusInd Bank, pharma 2026-08-10T04:55:10+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet The Hindu Business Line reports Signature Global awarded Rs 920 crore in construction contracts to KEC International and NCC for 11 towers at its Dwarka Expressway project. Work starts in Q3 FY27. IndusInd Bank got RBI approval for a stockbroking subsidiary. In pharma, Novartis India ended its Dr Reddy's distribution pact, Emcure Pharma received a USFDA inspection closure (VAI classification), and AstraZeneca got CDSCO clearance for a breast cancer drug. Gland Pharma signed a sterile injectable manufacturing deal. RITES inked an HPCL MoU for railway siding consultancy. Neetu Yoshi starts production on September 13, 2026, and Fujiyama Power commissioned a 2 GW plant in Madhya Pradesh. ## Coverage - thehindubusinessline.com Tags: IndusInd Bank, pharma, railway, RBI, Signature Global, stock market Canonical: https://indianopinion.org/20-stocks-in-focus-signature-global-indusind-bank-pharma/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/20-stocks-in-focus-signature-global-indusind-bank-pharma/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.